AstraZeneca, Oracle Join Forces to Use AI in Clinical Trials, Target Faster Drug Development
Bengaluru: AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research.
The collaboration will combine AstraZeneca's drug development expertise with Oracle's AI and healthcare data capabilities to support patient matching and research
Initial work will focus on cancer, cardiovascular, respiratory, immunology and rare diseases, and could also support earlier diagnosis of serious diseases
The first project will support hypertension research in Abu Dhabi in partnership with UA0E-based healthcare firm M42
Patient recruitment remains one of the biggest challenges in clinical research, with delayed enrolment often extending trial timelines and increasing development costs
Incorrect trial designs have also hurt AstraZeneca in the past, with delays on its breast cancer drug and nerve disorder treatment failure causing some worries
AstraZeneca is seeking to expand its medicine portfolio as it targets over $80 billion in annual revenue by 2030, and works to address industry bottlenecks in drug development.
